Kantle's acquisition of Baiji new special pharmacy drug retail industry is facing reshuffle

Source: Bio exploration 2013-11-29 when kantle "ate" Baiji new special pharmacy "spent the winter" in the pharmacy industry, the international pharmaceutical distribution giant started the merger and acquisition As one of the world's top 100 enterprises and the second largest healthcare service provider in the United States, kantle has recently formally acquired Guangzhou Baiji Xinte pharmaceutical chain Co., Ltd (Baiji Xinte) as its major shareholder According to the public information, since the establishment of the first specialized pharmacy in South China in 2002, Baiji Xinte Pharmaceutical Co., Ltd has been focusing on the treatment of major chronic diseases It has established 19 branches in Guangzhou, Beijing, Shanghai, Shenzhen and other cities, becoming the largest specialized pharmaceutical chain enterprise in China At present, the annual sales scale is about 200 million yuan The services of kantle group extend to more than 340 cities, 65000 hospitals and 148000 retail pharmacies around the world, with more than 500 pharmaceutical factories and 11 logistics centers In 2012, the operating revenue is 102.6 billion US dollars, ranking 61 in the world's top 500 In fact, the drug retail industry is facing a reshuffle Kantle's "enclosure movement" has long started In 2011, kantle acquired Yongyu pharmaceutical, the largest foreign pharmaceutical company in China, with us $470 million, and received its 9 major logistics centers and sales channels in 330 cities in China, thus rapidly entering the Chinese pharmaceutical distribution market In August of that year, kantle acquired Sichuan Hewei pharmaceutical consulting Management Co., Ltd.; in December of that year, kantle acquired Wuxi Xishan Pharmaceutical Co., Ltd., and then Zhejiang Dasheng Pharmaceutical Co., Ltd., Shenzhen Hedan Pharmaceutical Co., Ltd and Dalian Zhongda Pharmaceutical Co., Ltd were successively "incorporated" by kantle In 2012, kantle ranked among the top 10 pharmaceutical commercial companies in China For the addition of Baiji Xinte, E medicine manager commented that it will further enhance the competitiveness of kantle in retail terminals The existing import drug distribution business of kantle can fully guarantee the upstream product supply of Baiji Xinte According to kantle's plan, Baiji Xinte operation team is responsible for the development of kantle pharmacy in China At this time, the domestic drug retail market is in a "cold winter" According to the data of RDM in the national drug retail market, the growth rate of the total scale of drug retail market continued to decline in 2013, with a year-on-year growth of 13.2% in the first half of the year In addition, medical reform, drug circulation, safety and other factors also affect the growth of drug retail industry Tan Quansheng, medical analyst of Jinyuan securities, said in an interview with the new express yesterday that bargain hunting is the best investment from the perspective of investment; from the perspective of global pharmaceutical development trend, the full marketization of pharmacy industry is in line with the choice of national welfare, and self medication is also a trend of modern social development; finally, the brand positioning of Baiji new specialty is new specialty medicine Tumor medicine, with distinct business characteristics, has its own unique differentiation in the pharmacy industry, with competitive advantages Another industry insiders said that when the domestic drug retail market is at a low ebb, domestic pharmacies should adjust as soon as possible to adapt to the changes in the environment, otherwise the story of "big fish eat small fish" will continue to play out Public information shows that at present, the pattern of small, scattered, disordered and poor pharmacies in China has not changed much The total number of various pharmacies exceeds 420000, but the chain rate is very low, and the proportion of large-scale chain pharmacies in the whole industry is less than half According to some data, the total turnover of the top three drug retail chains in China is less than 10% of the total market share, while the market share of the top three drugstores in the United States is more than 70%.